TI
GPCR icon

TrueMark Investments’s Structure Therapeutics GPCR Stock Holding History

TrueMark Investments’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Sell
33,600
-777
-2% -$34.4K 0.23% 83
2026
Q1 		$1.66M Buy
34,377
+484
+1% +$33.1K 0.32% 68
2025
Q4 		$2.36M Sell
33,893
-968
-3% -$39.5K 0.45% 63
2025
Q3 		$976K Sell
34,861
-2,904
-8% -$57.8K 0.17% 126
2025
Q2 		$783K Sell
37,765
-1,452
-4% -$31.9K 0.17% 123
2025
Q1 		$679K Sell
39,217
-2,910
-7% -$71.3K 0.18% 105
2024
Q4 		$1.14M Sell
42,127
-3,353
-7% -$119K 0.36% 85
2024
Q3 		$2M Buy
45,480
+15,596
+52% +$603K 0.64% 59
2024
Q2 		$1.17M Hold
29,884
– – 0.4% 87
2024
Q1 		$1.28M Buy
29,884
+3,562
+14% +$150K 1.18% 39
2023
Q4 		$1.07M Buy
+26,322
New +$1.51M 1.07% 47

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

TrueMark Investments's GPCR Position: Q2 2026 in Review

TrueMark Investments reduced its Structure Therapeutics (GPCR) stake by 2.3% in Q2 2026, selling an estimated $34.4K and leaving 33,600 shares worth $1.8M. The position accounts for 0.23% of the portfolio, ranked #83.

TrueMark Investments first reported a position in GPCR in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.36M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • TrueMark Investments held 33,600 shares of Structure Therapeutics worth $1.8M as of Q2 2026.
  • TrueMark Investments sold 777 Structure Therapeutics shares in Q2 2026, an estimated $34.4K.
  • Structure Therapeutics made up 0.23% of TrueMark Investments's portfolio in Q2 2026, its #83 holding.
  • TrueMark Investments first reported a position in Structure Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • TrueMark Investments's Structure Therapeutics position peaked at $2.36M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on TrueMark Investments's 13F filing for Q2 2026, filed 22 Jul 2026.